116 related articles for article (PubMed ID: 16197815)
1. Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis.
Nagano I; Shiote M; Murakami T; Kamada H; Hamakawa Y; Matsubara E; Yokoyama M; Moritaz K; Shoji M; Abe K
Neurol Res; 2005 Oct; 27(7):768-72. PubMed ID: 16197815
[TBL] [Abstract][Full Text] [Related]
2. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
3. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.
Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M;
J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433
[TBL] [Abstract][Full Text] [Related]
4. IGF-1:tetanus toxin fragment C fusion protein improves delivery of IGF-1 to spinal cord but fails to prolong survival of ALS mice.
Chian RJ; Li J; Ay I; Celia SA; Kashi BB; Tamrazian E; Matthews JC; Bronson RT; Rossomando A; Pepinsky RB; Fishman PS; Brown RH; Francis JW
Brain Res; 2009 Sep; 1287():1-19. PubMed ID: 19563785
[TBL] [Abstract][Full Text] [Related]
5. Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity.
Saenger S; Holtmann B; Nilges MR; Schroeder S; Hoeflich A; Kletzl H; Spooren W; Ostrowitzki S; Hanania T; Sendtner M; Metzger F
Amyotroph Lateral Scler; 2012 Sep; 13(5):418-29. PubMed ID: 22871074
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.
Lewis ME; Neff NT; Contreras PC; Stong DB; Oppenheim RW; Grebow PE; Vaught JL
Exp Neurol; 1993 Nov; 124(1):73-88. PubMed ID: 8282084
[TBL] [Abstract][Full Text] [Related]
7. The GH-IGF system in amyotrophic lateral sclerosis: correlations between pituitary GH secretion capacity, insulin-like growth factors and clinical features.
Pellecchia MT; Pivonello R; Monsurrò MR; Trojsi F; Longo K; Piccirillo G; Pivonello C; Rocco M; Di Somma C; Colao A; Tedeschi G; Barone P
Eur J Neurol; 2010 May; 17(5):666-71. PubMed ID: 20002733
[TBL] [Abstract][Full Text] [Related]
8. Free insulin-like growth factor (IGF)-1 and IGF-binding proteins-2 and -3 in serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients.
Corbo M; Lunetta C; Magni P; Dozio E; Ruscica M; Adobbati L; Silani V
Eur J Neurol; 2010 Mar; 17(3):398-404. PubMed ID: 19845745
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group.
Desnuelle C; Dib M; Garrel C; Favier A
Amyotroph Lateral Scler Other Motor Neuron Disord; 2001 Mar; 2(1):9-18. PubMed ID: 11465936
[TBL] [Abstract][Full Text] [Related]
10. Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS.
Gordon PH; Cheng B; Katz IB; Mitsumoto H; Rowland LP
Neurology; 2009 Jun; 72(22):1948-52. PubMed ID: 19487653
[TBL] [Abstract][Full Text] [Related]
11. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group.
Lai EC; Felice KJ; Festoff BW; Gawel MJ; Gelinas DF; Kratz R; Murphy MF; Natter HM; Norris FH; Rudnicki SA
Neurology; 1997 Dec; 49(6):1621-30. PubMed ID: 9409357
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of PEGylated insulin-like growth factor I in the pmn mouse model of motoneuron disease.
Jablonka S; Holtmann B; Sendtner M; Metzger F
Exp Neurol; 2011 Dec; 232(2):261-9. PubMed ID: 21963648
[TBL] [Abstract][Full Text] [Related]
13. Rates of progression of weight and forced vital capacity as relevant measurement to adapt amyotrophic lateral sclerosis management for patient Result of a French multicentre cohort survey.
Clavelou P; Blanquet M; Peyrol F; Ouchchane L; Gerbaud L
J Neurol Sci; 2013 Aug; 331(1-2):126-31. PubMed ID: 23809193
[TBL] [Abstract][Full Text] [Related]
14. Neurotrophic and Neuroregenerative Effects of GH/IGF1.
Bianchi VE; Locatelli V; Rizzi L
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29149058
[TBL] [Abstract][Full Text] [Related]
15. A randomized sequential trial of creatine in amyotrophic lateral sclerosis.
Groeneveld GJ; Veldink JH; van der Tweel I; Kalmijn S; Beijer C; de Visser M; Wokke JH; Franssen H; van den Berg LH
Ann Neurol; 2003 Apr; 53(4):437-45. PubMed ID: 12666111
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor system in amyotrophic lateral sclerosis.
Wilczak N; Keyser J
Endocr Dev; 2005; 9():160-169. PubMed ID: 15879696
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of insulin-like growth factor-I on wobbler mouse motoneuron disease.
Hantaï D; Akaaboune M; Lagord C; Murawsky M; Houenou LJ; Festoff BW; Vaught JL; Rieger F; Blondet B
J Neurol Sci; 1995 May; 129 Suppl():122-6. PubMed ID: 7595602
[TBL] [Abstract][Full Text] [Related]
18. Oropharyngeal dysphagia in amyotrophic lateral sclerosis: neurological and dysphagia specific rating scales.
Kidney D; Alexander M; Corr B; O'toole O; Hardiman O
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5(3):150-3. PubMed ID: 15512903
[TBL] [Abstract][Full Text] [Related]
19. IGF-I prevents glutamate-induced motor neuron programmed cell death.
Vincent AM; Mobley BC; Hiller A; Feldman EL
Neurobiol Dis; 2004 Jul; 16(2):407-16. PubMed ID: 15193297
[TBL] [Abstract][Full Text] [Related]
20. Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model.
Ishigaki A; Aoki M; Nagai M; Warita H; Kato S; Kato M; Nakamura T; Funakoshi H; Itoyama Y
J Neuropathol Exp Neurol; 2007 Nov; 66(11):1037-44. PubMed ID: 17984685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
